Table 2.
Patients’ characteristics.
| N (%) | ||
|---|---|---|
| Age (years) | < 65 | 146 (70.9%) |
| ≥ 65 | 60 (29.1%) | |
| Sex | Female | 124 (60.2%) |
| Male | 82 (39.8%) | |
| Stage | IIIA–IIIB | 11 (5.3%) |
| IV | 195 (94.7%) | |
| Metastatic site | Bone | 111 (53.9%) |
| Lung | 55 (26.7%) | |
| Brain | 39 (18.9%) | |
| Pleura | 35 (17%) | |
| Liver | 26 (12.6%) | |
| Adrenals | 11 (5.3%) | |
| Spleen | 4 (1.9%) | |
| Pericardium | 4 (1.9%) | |
| Others | 7 (3.4%) | |
| Mutation_type | EGFR | 183 (88.8%) |
| ALK | 17 (8.2%) | |
| HER2 | 1 (0.5%) | |
| CMET | 2 (1.0%) | |
| ROS1 | 3 (1.5%) | |
| Combination therapy | No | 91 (44.2%) |
| Chemotherapy | 93 (45.1%) | |
| Anti-angiogenic therapy | 55 (26.7%) | |
| Radiotherapy | 15 (7.3%) | |
| Targeted drugs | Gefitinib | 104 (50.5%) |
| Erotinib | 22 (10.7%) | |
| Icotinib | 16 (7.8%) | |
| Osimertinib | 18 (8.7%) | |
| Almonertinib | 6 (2.9%) | |
| Afatinib | 15 (7.3%) | |
| Alectinib | 9 (4.3%) | |
| Cozotinib | 13 (6.3%) | |
| Pyrotinib | 1 (0.5%) | |
| Dacomitinib | 2 (1.0%) | |
| Markers | CEA | 188 (91.3%) |
| CA125 | 9 (4.3%) | |
| CA199 | 6 (2.9%) | |
| CA153 | 3 (1.5%) | |
Abbreviation:
EGFR, the epidermal growth factor receptor. ALK, anaplastic lymphoma kinase. ROS1, ROS proto-oncogene 1, receptor tyrosine kinase. RET, rearranged during transfection, CMET, C-Mesenchymal-epithelia transition factor, and HER2, human epidermal growth 2; CEA, carcinoembryonic antigen; CA199, carbohydrate antigen 19-9; CA125, carbohydrate antigen 125; CA153, carbohydrate antigen 153.